ArticleFrontiers in oncology2026
Serum metabolomic profiles associated with psychoneurological symptoms in women with early-stage breast cancer over one year.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Background: Breast cancer survivors frequently experience psychoneurological symptoms (PNS), such as pain, fatigue, anxiety, depression, and sleep disturbances, that persist beyond treatment and impair quality of life. Inflammatory and metabolic dysregulation, including alterations in the tryptophan/kynurenine pathway, have been implicated, yet longitudinal data and racial differences remain understudied. This study examined the longitudinal association between metabolite levels and PNS severity over time and explored their interactions with race. Methods: In a one-year longitudinal secondary data analysis, we performed untargeted serum metabolomic profiling and applied generalized estimating equations (GEE), adjusting for demographic covariates. Interaction terms were included to evaluate race-specific metabolite associations. Metabolite set enrichment analysis was conducted to identify impacted metabolic super-pathways using MetaboAnalyst 6.0. Results: Among 74 participants, we identified 140 metabolites significantly associated with PNS out of the 2,395 metabolites tested, with 38 named metabolites. Anxiety was associated with 2-aceto-2-hydroxy-butanoate (β=-2.40, p=5.79×10-6) and 1-pyrrolidinecarboxaldehyde (β=-0.753, p=8.61×10-6), while sleep disturbance associated with 4,6-O-ethylidene-D-glucose (β=9.83, p=4.82×10-6) and 5-hydroxytryptophol (β=7.82, p=5.55×10-4). Fatigue showed the most associations, including 3-hydroxystachydrine (β=1.02, p=3.79×10-8) and N-acetylglycine (β=0.927, p=5.89×10-5), and pain were associated with inulin (β=-3.19, p=5.39×10-5). Associations between race and PNS-metabolite interactions revealed unique patterns for Black women, particularly for sleep disturbances, pain and fatigue. Taurine/hypotaurine and cysteine metabolism were the most impacted pathways in the enrichment analysis. Conclusions: These findings highlight distinct metabolite profiles underlying PNS and suggest that sulfur amino acid- and oxidative stress-related pathways may contribute to symptom variability. Specific metabolites may reflect underlying metabolic pathway differences across racial groups. These results provide a foundation for future mechanistic studies and metabolically targeted interventions in cancer survivorship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.